Earnings Roundup: Centene's Medicaid Miracle

Centene (CNC) joined United Healthcare (UNH) in reporting impressive Medicaid revenue, setting the stage for Molina (MOH) to beat when it reports on May 1st.

Apr 22, 2014 at 6:30PM

Centene (NYSE:CNC) reported better-than-hoped results thanks to surging Medicaid enrollment tied to the launch of Obamacare last fall.

The private Medicaid insurer's results came after UnitedHealth Group (NYSE:UNH), the largest U.S. insurer, reported that Medicaid was its best growing insurance business last quarter.

Despite the highly publicized jump in Medicaid enrollment, investors were apparently caught flat footed. Shares soared more than 12% by mid-day. Given the big pop, let's take a closer look at Centene's first quarter results.

CNC Chart

CNC data by YCharts

A big bump to sales and earnings
Private Medicaid insurers like Centene do all the work behind the scenes for state Medicaid programs. States contract with providers like Centene, United Healthcare, and Molina (NYSE:MOH) to administer those programs, paying a fee based on the number of Medicaid members signed up in each state.

In the first quarter, membership in plans run by Centene climbed 13% to nearly 2.9 million people. 218,000 of those new members were covered by Centene's Medicaid plans. The significant hike in enrollees led to revenue climbing a third to $3.35 billion.

Even better, the costs associated with providing care to those Medicaid members fell. The medical care ratio, or MCR, declined by almost one percentage point from last year.

That led to earnings per share reaching $0.57, up from $0.44 last year, and nicely above Wall Street's pre-earnings expectations for $0.45.

Importantly, the results were strong enough to support Centene upping its full year revenue forecast to $14.2 billion to $14.8 billion. Overall, Centene expects earnings per share to total $3.60 to $3.90 this year. That's up from its earlier prediction of $13.8 billion to $14.3 billion in sales and $3.50 to $3.80 per share in earnings. Given the Street is expecting just $3.62, analysts are likely already updating their models to reflect the potential upside opportunity.

An industry-wide boom
According to the Center for Medicaid and Medicare Services, or CMS, 3 million people signed up for Medicaid following the launch of Obamacare last fall. That growth came in spite of many states opting out of the reform law's Medicaid expansion, which included increasing eligibility to those earning up to 138% of the federal poverty line.

That expansion means that the industry is enjoying the biggest gift since managed Medicaid was introduced in the 1980's.

The first quarter results will give investors additional clarity into how this jump in sales will translate into profit. The early read last quarter, which included new members added in the fourth quarter, was overwhelmingly positive.

At Molina, sales jumped to $1.7 billion in the fourth quarter, up from $1.58 billion a year ago. That lifted full year sales from $5.9 billion to $6.58 billion. While that's solid growth, sales this year should accelerate significantly.

In February, Molina updated its full year 2014 guidance. Molina expects sales to hit $9.9 billion, leading to EPS of between $4 and $4.5. If Molina can deliver on that forecast, it will mark a big improvement from the $3.13 the company posted in 2013.

So far signs suggest that the industry's growth will indeed impress. UnitedHealth Group told investors last week that while commercial enrollment in its plans slumped last quarter, Medicaid enrollment grew 10%. As a result, United's Medicaid revenue grew 17% to $5.2 billion.

Fool-worthy final thoughts
Private Medicaid is a low margin business. Operating margin at Centene and Molina is substantially lower than the much more diversified United Healthcare.

As a result, Centene's business is one uniquely driven by volume, and that's in no short supply this year following the enrollment pop. That suggests investors should continue to be rewarded throughout 2014.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not own positions in the companies mentioned. The Motley Fool recommends UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information